Last reviewed · How we verify
Herceptin (Trastuzumab-Qyyp)
Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity.
Trastuzumab-Qyyp (TRAZIMERA) is a HER2-targeted monoclonal antibody indicated for HER2-overexpressing breast cancer (adjuvant and metastatic) and metastatic gastric/gastroesophageal junction adenocarcinoma. The drug demonstrates strong efficacy through HER2 receptor antagonism and antibody-dependent cellular cytotoxicity with no absolute contraindications. Key risk includes cardiac dysfunction when anthracyclines are used within 7 months of trastuzumab discontinuation due to prolonged washout. Patient selection requires FDA-approved HER2 companion diagnostic testing for all indications.
At a glance
| Generic name | Trastuzumab-Qyyp |
|---|---|
| Sponsor | Roche |
| Drug class | HER2/neu receptor antagonist monoclonal antibody |
| Target | HER2 (c-erbB2) proto-oncogene transmembrane receptor protein |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1998 |
Mechanism of action
Trastuzumab binds to the HER2 transmembrane receptor protein (185 kDa), which is structurally related to the epidermal growth factor receptor and is overexpressed in certain cancers. The drug inhibits proliferation of human tumor cells that overexpress HER2 through both in vitro assays and animal models. Trastuzumab products are mediators of antibody-dependent cellular cytotoxicity (ADCC), with in vitro studies demonstrating that trastuzumab-mediated ADCC is preferentially exerted on HER2-overexpressing cancer cells compared with cancer cells that do not overexpress HER2.
Approved indications
- HER2-positive carcinoma of breast
- HER2-positive colon cancer
- HER2-positive rectal cancer
- HER2-positive salivary gland tumors
- Human epidermal growth factor 2 positive gastric cancer
- Secondary malignant neoplasm of female breast
- Secondary malignant neoplasm of stomach
Common side effects
- Fatigue
- Alopecia
- Nausea
- Diarrhea
- Peripheral sensory neuropathy
- Anemia
- Mucositis oral
- Neutrophil count decreased
- Dermatitis radiation
- Myalgia
- Bone pain
- Vomiting
Drug interactions
- Anthracyclines
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Herceptin CI brief — competitive landscape report
- Herceptin updates RSS · CI watch RSS
- Roche portfolio CI